SCHIZOPHRENIA

This study tests a new drug called Ulotaront (SEP-363856) to see if it can reduce symptoms like hallucinations and delusions in people with schizophrenia. About 522 adults experiencing an acute episode will receive either the drug or a placebo for 6 weeks. The main goal is to mea…

This phase 3 trial is testing whether the drug KarXT can safely and effectively treat schizophrenia in adolescents aged 13 to 17. About 166 teens will receive either KarXT or a placebo, and researchers will track changes in symptoms like delusions and social withdrawal. The goal …

This phase 3 study tests whether KarXT, a new drug, can safely reduce schizophrenia symptoms in 250 Japanese adults experiencing acute psychosis. Participants first receive either KarXT or a placebo for 5 weeks, then all may receive KarXT for a year. The goal is to see if KarXT i…

This early-stage study is testing a single injection of a long-acting form of the drug brexpiprazole in healthy volunteers and people with schizophrenia. The main goal is to check if the injection is safe and tolerable, and how the body processes the drug. The trial involves 56 p…

This study is checking the long-term safety of a drug called KarXT in teenagers (13-17) with schizophrenia, and a combination of KarXT and KarX-EC in children (5-17) with irritability linked to autism. About 400 participants who completed earlier studies will take the drug for up…

This study tests whether adding brenipatide to standard schizophrenia medication is safe and effective. About 450 adults with schizophrenia will receive either brenipatide or a placebo for up to 12 months. The study looks at weight changes, cognitive function, and time to relapse…

This study is tracking 300 adults with schizophrenia in the U.S. who are prescribed a new drug called xanomeline and trospium chloride (X/T). Researchers want to know if patients prefer this drug over their previous treatment and how satisfied they are with it. The study will als…

This study tracks 1,500 adults with schizophrenia who start taking KarXT (xanomeline and trospium chloride) in routine clinical care across the U.S. Researchers will monitor how doctors adjust doses, side effects, weight changes, and relapses over time. The goal is to understand …

This study tests whether adding sodium benzoate—a substance that affects brain glutamate—to standard antipsychotic medication can improve symptoms and thinking in people with treatment-resistant schizophrenia. About 90 adults who have not responded well to at least two antipsycho…

This study tests whether valbenazine can reduce involuntary muscle movements (tardive dyskinesia) in adults who still have symptoms while taking or after stopping another similar drug. About 50 people with schizophrenia, bipolar disorder, or major depression will take valbenazine…

This early-stage study is testing a long-acting injectable form of the drug KarXT in 116 people with schizophrenia. The main goal is to check the drug's safety and how the body processes it. Researchers hope this injectable version could offer a more convenient treatment option t…

This early-stage trial tests whether the experimental drug aticaprant is safe and tolerable when added to standard antipsychotic treatment for schizophrenia. About 64 clinically stable outpatients will receive either aticaprant or a placebo. The main goals are to see if the study…

This Phase 3 trial tests whether the experimental drug NBI-1117568 can delay relapse of schizophrenia symptoms compared to a placebo. About 560 adults with stable schizophrenia will first receive the drug openly, then be randomly assigned to continue it or switch to placebo. The …

This phase 3 trial is testing the long-term safety of the drug NBI-1117568 in 600 adults with schizophrenia. Participants will receive the drug and be monitored for side effects over time. The study is open-label, meaning everyone knows they are getting the drug, and it focuses o…

This study tests whether a combination drug called OLZ/SAM (olanzapine plus samidorphan) causes less weight gain than olanzapine alone in teenagers with schizophrenia or bipolar I disorder. About 220 teens aged 10-17 will take either the combo or olanzapine for 52 weeks. The main…

This study tests whether the diabetes drug metformin can prevent blood sugar increases caused by statins in people with schizophrenia. Researchers will give 400 patients either metformin or a placebo alongside atorvastatin for six months. The goal is to see if metformin helps kee…

This study is testing how the drug KarXT affects bladder function and overall safety in 60 adults with schizophrenia over 12 months. Participants will stop their current antipsychotics and take KarXT to see if it causes any urinary problems. The goal is to ensure the drug is safe…

This study tests whether using a person's genetic information to guide medication choices leads to better recovery for people with mood, anxiety, or psychotic disorders. Over 2,500 participants will receive either standard care or personalized medication advice based on their gen…

This study tests a new drug called NBI-1117570 in 120 adults with schizophrenia who need hospital care. The goal is to see if it improves symptoms like hallucinations and disorganized thinking better than a placebo. Participants take the drug or a placebo daily for 35 days, and r…

This study tests whether adding lumateperone (Caplyta) to clozapine can reduce common side effects like weight gain and high blood sugar in people with schizophrenia or schizoaffective disorder. Fifty participants will take either lumateperone or a placebo for 12 weeks while cont…

This Phase 3 trial tests whether a new drug called NBI-1117568 can improve schizophrenia symptoms like hallucinations and disorganized thinking. About 284 adults with schizophrenia who need hospital care will receive either the drug or a placebo for 5 weeks. The study measures sy…

This study tests a smartphone app that uses motion-sensing cognitive games and interactive stories to help people with schizophrenia improve their thinking, mood, and daily skills. 84 hospitalized adults will be randomly assigned to use the app or receive standard care. The goal …

This study compares clozapine and risperidone in people with schizophrenia, schizoaffective disorder, or bipolar I disorder with psychosis. Researchers want to see if a specific brain biotype (Biotype-1) responds better to clozapine. About 320 participants will be randomly assign…

This study is testing whether clozapine, a medication for schizophrenia, can reduce violent acts better than other antipsychotic drugs. Researchers will enroll 280 people with schizophrenia or schizoaffective disorder who have been violent in the past six months. Participants wil…

This study tests whether a non-invasive brain stimulation technique called tDCS can reduce cannabis use in people with schizophrenia. 110 motivated participants will receive either real or sham stimulation over 5 days. Researchers will track changes in cannabis consumption, cravi…

This study tests a new drug, LB 102, to see if it helps reduce schizophrenia symptoms better than a placebo. About 456 adults with acute schizophrenia will take either the drug or a placebo for 6 weeks while staying in the hospital. The main goal is to measure changes in symptoms…

This study tests a long-acting injection of cariprazine given once a month, instead of daily pills, for people with schizophrenia, bipolar I disorder, or major depression. The trial involves 24 clinically stable adults and will check safety, side effects, and how well the drug wo…

This early-stage study tests a new drug called VV119 in healthy adults and people with schizophrenia. The main goal is to check if the drug is safe and how the body processes it. About 40 participants will take multiple doses to find the right amount for future studies.

This study is testing a new drug called ML-007C-MA for adults with schizophrenia. The goal is to see if it is safe and works well over a full year. About 500 people who have recently been in a related study or are new to the trial will take the drug twice daily. Researchers will …

This study looks at whether taking antipsychotic medication every other day is as effective as taking it daily for people with schizophrenia. 120 participants will be randomly assigned to either daily dosing or every-other-day dosing for one year. The goal is to see if extended d…

This study is testing whether a daily synbiotic supplement (a mix of probiotics and prebiotics) can reduce symptoms of schizophrenia when taken alongside standard antipsychotic medications. Researchers are enrolling 68 adults with schizophrenia or schizoaffective disorder who hav…

This study tests whether ocrelizumab, a drug that suppresses certain immune cells, can reduce psychosis symptoms in people whose schizophrenia or bipolar disorder may be caused by auto-antibodies attacking brain receptors. Forty participants aged 18–35 will receive either ocreliz…

This study tests whether a new generic version of a 3-month schizophrenia injection works the same as the brand-name drug Invega Trinza. About 260 Chinese adults with stable schizophrenia will receive multiple doses of either the test or reference drug. The goal is to see if the …

This study tests whether adding an anti-inflammatory drug to an NMDA-enhancing agent can improve thinking and memory in people with ultra-resistant schizophrenia. About 80 adults who have not responded well to clozapine will receive the combination or a placebo. The goal is to se…

This study looks at the long-term safety of an investigational drug called KarXT when added to current antipsychotic medications for people with schizophrenia. About 280 adults who completed a previous KarXT study will take the drug for up to 52 weeks. Researchers will track side…

This study tests whether a prebiotic supplement (Prebiotin®) can reduce inflammation and improve thinking in people with schizophrenia or schizoaffective disorder. Sixty adults aged 18-60 who are stable on antipsychotics will take the prebiotic or a placebo for 12 weeks. Research…

This study tests whether adding five extra services—like peer support, digital outreach, and group therapy—to standard care helps people with early psychosis stay in treatment longer. About 350 participants will either receive standard care or the enhanced program. Researchers wi…

This study tests whether tirzepatide, a drug used for diabetes and obesity, can help people with both schizophrenia and alcohol use disorder drink less. Researchers will give weekly injections of tirzepatide or a placebo to 108 participants for 16 weeks, tracking heavy drinking d…

This study looks at whether stopping unnecessary anticholinergic drugs (benztropine or trihexyphenidyl) can improve thinking, quality of life, and brain function in people aged 40-70 with schizophrenia or schizoaffective disorder. Participants will either stay on their medication…

This Phase 2 study tests an investigational drug called emraclidine in about 268 adults with schizophrenia. The trial has two parts: Part A looks at how the drug moves through the body and its safety at different doses, while Part B measures whether it improves symptoms like hall…

This study tests whether adding empagliflozin, a diabetes drug, can reduce weight gain and other metabolic side effects caused by olanzapine in people with schizophrenia. Forty adults aged 18 to 60 who take olanzapine will receive either empagliflozin or a placebo for several wee…

This study compares Magnetic Seizure Therapy (MST) to standard Electroconvulsive Therapy (ECT) in 80 people with treatment-resistant schizophrenia or schizoaffective disorder. MST uses magnetic pulses to trigger a controlled seizure, aiming to ease symptoms like hallucinations an…

This study looks at whether maintenance electroconvulsive therapy (ECT) can prevent relapse in people with schizophrenia that doesn't respond to the strongest medications. About 140 participants who improved after a course of ECT will either continue with maintenance ECT or recei…

This study tests whether giving stronger medications earlier can help people with schizophrenia, major depression, or bipolar depression who did not get better with their first treatment. Over 1,200 participants will receive either standard second-line treatment or an intensified…

This phase 3 trial is testing the long-term safety of a daily pill called SEP-363856 for adults with schizophrenia. Researchers will monitor 100 Japanese participants for side effects over 52 weeks. The goal is to see if this drug can be a safe option for ongoing disease control.

This study tests whether giving e-cigarettes to smokers with mental illness—along with optional behavioral coaching—helps them switch from regular cigarettes and lower their exposure to harmful chemicals. The trial enrolls 250 daily smokers who have tried to quit before but aren'…

This study tests whether a long-acting injection of iloperidone can delay or prevent the return of schizophrenia symptoms compared to a placebo injection. About 400 adults with schizophrenia who need ongoing treatment will receive either the drug or a placebo and be monitored for…

This study tests a program called Taking Action, where trained peers help college students with serious mental illnesses like depression, bipolar disorder, or schizophrenia learn to manage their condition. About 300 students will be randomly assigned to either the program or just…

This study tests a new treatment called magnetic seizure therapy (MST) for people with psychotic disorders like schizophrenia. MST uses magnetic pulses to trigger a controlled seizure in the brain, aiming to improve symptoms when added to standard antipsychotic medications. The t…

This Phase 1 trial tests the safety and tolerability of a new extended-release tablet called LY03020 in 40 Chinese adults, including healthy volunteers and people with stable schizophrenia. The drug is also being explored for psychosis related to Alzheimer's disease. Participants…

This study tests whether cariprazine, a daily medication, can safely reduce schizophrenia symptoms in teenagers aged 13 to 17. About 330 participants will receive either cariprazine or a placebo for 6 weeks. The main goal is to see if symptoms improve compared to a placebo.

This study looks at whether giving a more powerful medication sooner can help people with schizophrenia who did not get better on their first treatment. About 418 adults will either receive the usual second-line treatment or an early intensified approach. The goal is to see if th…

This study tests different ways to start taking olanzapine, a common schizophrenia medication, to see if a slower dose increase can reduce side effects while still controlling symptoms. About 120 adults with schizophrenia will receive one of several dosing schedules or a placebo.…

This study tests whether yoga-based exercises can help veterans with schizophrenia, schizoaffective disorder, or bipolar 1 disorder improve their ability to function in daily life—like socializing, working, and managing leisure activities. About 112 veterans will be randomly assi…

This study tests an experimental oral drug called GXV813 in 142 hospitalized adults with schizophrenia. The goal is to see if it safely reduces symptoms like hallucinations and withdrawal during an acute episode. Participants are randomly assigned to receive GXV813 or a placebo, …

This study tests a new medicine called KYN-5356 to see if it can help with thinking and memory problems in people with schizophrenia. About 150 adults who are stable on their current schizophrenia treatment will take either a low, medium, or high dose of the drug or a placebo for…

This study tests a new drug called roluperidone for treating negative symptoms of schizophrenia, like lack of motivation and social withdrawal. About 380 adults with schizophrenia will take the drug or a placebo for 12 weeks to see if symptoms improve. Then, for 40 more weeks, re…

This study tests whether training mental health professionals to deliver a short psychoeducational program (BREF) can reduce the burden on caregivers of people with schizophrenia or first psychotic episode. The trial will include 206 caregivers, comparing those who receive the pr…

This study tests whether infliximab, an anti-inflammatory drug used for arthritis, can improve motivation and brain activity in people with schizophrenia who have high inflammation. Sixty adults with schizophrenia will receive either infliximab or a placebo, and researchers will …

This study tests whether low-intensity ultrasound, aimed at the brain, is safe and could help with schizophrenia symptoms. Eighty adults with schizophrenia will receive the non-invasive treatment. Researchers will check safety and look for any improvements in mood, thinking, and …

This study tests whether bazedoxifene, a drug that mimics estrogen, can help reduce schizophrenia symptoms in women when added to their usual antipsychotic medication. 160 women aged 18-65 with schizophrenia or related disorders will receive either bazedoxifene or a placebo daily…

This study tests whether people with schizophrenia who hear voices that medication doesn't help can learn to quiet them using a special brain-training technique. Participants get real-time feedback from an fMRI scanner to help them shift their brain activity away from the halluci…

This study tests whether learning music—rhythm, singing, and body movements—can improve attention and thinking in people with schizophrenia. About 120 adults with stable schizophrenia will take part. The goal is to see if music-based training is a more engaging and effective way …

This study tests whether playing specially designed somatosensory video games for 2 months can improve thinking skills in people with schizophrenia. The games train five cognitive functions like memory and attention using body movements. Researchers will enroll 84 stable patients…

This study tests a 6-week group therapy program for adults with schizophrenia or related disorders. The therapy focuses on changing negative core beliefs (like feeling worthless or that others are dangerous) using compassion-focused techniques. The goal is to see if this approach…

This study tests a new type of transcranial magnetic stimulation (TMS) that targets three brain areas at once to help with negative symptoms of schizophrenia, like lack of motivation, emotion, or social interest. Researchers will enroll 64 people with first-episode schizophrenia …

This study tests whether a low dose of buprenorphine (0.15 mg) can improve social motivation in 40 people with schizophrenia. Participants will take either the drug or a placebo and complete tasks that measure their drive to seek or avoid social interaction. The goal is to see if…

This study tests a virtual reality program designed to help people with psychosis improve their thinking and social skills. The program was created with input from patients and doctors. Researchers will see if it is practical and helpful for daily life. The study involves 52 adul…

This early-stage trial tests BXCL501, a dissolving film placed under the tongue, to quickly reduce agitation in children and teens aged 10-17 with schizophrenia or bipolar disorder. About 140 participants will receive either the drug or a placebo. The study measures changes in ag…

This study tests whether acetazolamide, a drug currently used for altitude sickness and glaucoma, can reduce positive symptoms (like hallucinations or delusions) in people with treatment-resistant schizophrenia. Sixty adults aged 18-55 who still have significant symptoms despite …

This study tests a drug that boosts NMDA activity as a standalone treatment for schizophrenia. It is for people who refuse or cannot tolerate standard antipsychotics. The trial will measure changes in symptoms like hallucinations and social withdrawal in 80 participants over seve…

This study tests whether adding a second drug that boosts NMDA receptors to a sigma-1 receptor agonist can better reduce schizophrenia symptoms than the sigma-1 drug alone. About 90 adults with schizophrenia who did not improve on at least two antipsychotics will take the combina…

This study is testing whether a non-invasive brain stimulation technique called repetitive transcranial magnetic stimulation (rTMS) applied to the cerebellum can improve cognitive deficits and mood in people with schizophrenia, autism, bipolar disorder, depression, or Parkinson's…

This study tests whether cromoglicate, a nasal spray used for allergies, can improve symptoms in people with schizophrenia or schizoaffective disorder. Researchers will give 160 adults either the active spray or a placebo, in addition to their usual medication. The goal is to see…

This early-stage trial is testing whether the drug MDMA (commonly known as ecstasy) is safe and tolerable for people with schizophrenia. The goal is to see if it can help with social withdrawal, a common and hard-to-treat symptom. Twenty stable participants will receive three dif…

This study tests an experimental drug, NBI-1117568, to see if it improves schizophrenia symptoms like hallucinations and delusions better than a placebo. About 284 adults with schizophrenia who need hospital care will take the drug or a placebo for 5 weeks. The main goal is to me…

This study tests whether a non-invasive brain stimulation technique called high-frequency transcranial alternating current stimulation (Hi-tACS) can improve cognitive problems like memory and attention in people with schizophrenia. One hundred participants will receive either rea…

This study tests whether a smartphone app called Kiso Mind is acceptable and helpful for people with schizophrenia or schizoaffective disorder. Sixty participants will either use the app plus their usual treatment, or just usual treatment alone, for 12 weeks. Researchers will mea…

This study tests a new virtual reality job training program for people with schizophrenia who want to work. About 40 adults aged 20 to 55 will practice job interviews and other skills in a safe VR environment. The goal is to see if this training helps improve symptoms and makes i…

This study tests whether breathing extra oxygen (normobaric oxygen therapy) can improve thinking, quality of life, and daily function in people who have had psychosis for less than 5 years. Twenty participants aged 15-35 will be randomly assigned to receive oxygen or a placebo. T…

This study tests whether a noninvasive brain stimulation technique called iTBS can improve working memory in people with early-stage schizophrenia. Researchers will use magnetic pulses and EEG to measure brain activity before and after stimulation. The goal is to see if iTBS can …

This study tests whether cognitive behavioral therapy (CBT) can help veterans with serious mental illness (like schizophrenia or bipolar disorder) who also have chronic low back pain. Researchers will measure changes in pain interference, quality of life, and pain severity after …

This study tests a therapy called Targeted Cognitive Training (TCT) for veterans with serious mental illnesses like schizophrenia, bipolar disorder, or PTSD. The goal is to improve thinking skills and daily functioning by using EEG brain scans to identify who will benefit most. A…

This study tests whether clay therapy can improve daily function and social performance in people with schizophrenia who are already on medication. Seventeen participants will take part in clay sessions, and researchers will measure changes in their ability to handle daily tasks …

This study tests a community-based cognitive remediation program for adults with schizophrenia or schizoaffective disorder. Participants do computer exercises and group sessions to improve memory, problem-solving, and social skills. The goal is to see if this helps them function …

This study tests whether repetitive transcranial magnetic stimulation (rTMS) can reduce depression in people with schizophrenia. About 180 adults will receive rTMS to the left prefrontal cortex. Researchers will measure changes in mood, thinking, and other symptoms over time.

This study tests whether a non-invasive brain stimulation technique called repetitive transcranial magnetic stimulation (rTMS) can help people with schizophrenia spectrum disorder quit or reduce smoking. Fifty participants will receive active rTMS using either an F8 coil or an H …

This phase 3 trial tests whether adding cannabidiol (CBD) to standard treatment can improve symptoms, thinking, and inflammation in people with early psychosis. About 120 adolescents and adults will receive either CBD or a placebo for 8 weeks. Researchers will also explore what f…

This study tests a 12-session group program called 'Better Together' for young adults with severe mental illness (like schizophrenia, bipolar disorder, or major depression) who are single and want to improve their romantic relationships. The program teaches communication, emotion…

This study tests whether a personalized form of brain stimulation called iTBS can help reduce schizophrenia symptoms in everyday clinic settings. Forty adults with schizophrenia will receive daily iTBS sessions for two weeks, while continuing their usual medications. Researchers …

This study tests whether a skin patch called ALTO-101 can improve cognitive function in people with schizophrenia who have thinking problems. About 82 participants will receive either the active patch or a placebo, then switch after a period. The main goal is to see changes in br…

This study tests whether a brain stimulation technique called repetitive transcranial magnetic stimulation (rTMS) can help ease depression in people with schizophrenia. Researchers will give up to 20 sessions of active or sham rTMS to 120 participants and use brain scans to see h…

This study tests whether a precise magnetic pulse to a specific brain area can improve negative symptoms like apathy and social withdrawal in people with schizophrenia. Forty participants will receive either real or sham stimulation daily for 10 days. Researchers will measure sym…

This study tests whether physical activity in green outdoor spaces reduces negative symptoms (like lack of motivation or social withdrawal) in people with schizophrenia more than indoor exercise. 45 adults aged 18-55 with persistent negative symptoms will participate. Researchers…

This study tests a 12-week group therapy program called Motivation Skills Training for people with schizophrenia or schizoaffective disorder. The goal is to see if it improves motivation, goal attainment, and quality of life compared to a control group focused on healthy behavior…

This study is testing a new social skills training program for Veterans with serious mental illness (like schizophrenia, bipolar disorder, or PTSD) who are looking for work. The program teaches skills to better understand social cues and handle workplace relationships. Researcher…

This pilot study tests whether a non-invasive magnetic brain stimulation technique called TMS can improve brain connectivity and thinking skills in people with schizophrenia. Forty adults will receive either real or sham TMS daily for four weeks, and researchers will measure chan…

This study tests whether real-time fMRI neurofeedback can help people with schizophrenia who still hear voices despite medication. Participants learn to control their own brain activity while inside an MRI scanner, aiming to reduce the brain signals linked to auditory hallucinati…

This study is testing whether an NMDA-enhancing drug can improve negative symptoms of schizophrenia (like lack of motivation or social withdrawal) and if it works better in men or women. 90 people with stable schizophrenia will receive either the drug or a placebo for several wee…

This study follows 178 people who had a first episode of psychosis to see how early treatment choices and relapses affect their thinking, daily life, and mental health over 20 years. Participants attend one interview to assess symptoms, thinking skills, and functioning. The goal …

This study aims to create a 'patient library' by collecting blood, stool, and hair samples from 250 people aged 15 to 30 who have had a first psychotic episode or are at high risk. Researchers will track their mental health over 10 years using the CAARMS test. The goal is to bett…

This study aims to create a French-language memory task that can be used during brain scans to measure source-monitoring—the ability to remember where information came from. Researchers will test the task on 120 people, including those with schizophrenia and healthy volunteers. T…

This study tests whether a 3-day training program called REFOCUS helps mental health teams provide care that supports personal recovery. About 760 people with severe mental disorders (like schizophrenia or bipolar disorder) will take part across 18 centers. Researchers will measu…

This study will follow 1,200 people with schizophrenia in Shanghai for up to 5 years. Researchers will track symptoms, aggression, and other mental health changes to understand how the disease progresses. The goal is to build a long-term database and biobank to improve future car…

This study looks at brain activity during sleep in people with early-course schizophrenia compared to healthy individuals. Researchers will play soft tones during deep sleep using a wearable headband to see if it can strengthen sleep-related brain waves and improve memory. The go…

This study is testing whether subtle changes in how people speak can predict who will develop schizophrenia. Researchers will record and analyze free speech from 215 young people aged 15-30 who are at ultra-high risk for psychosis. By using computer programs to detect semantic an…

This study explores whether a non-invasive brain stimulation technique called rTMS can reduce cannabis cravings in people with schizophrenia or schizoaffective disorder. Researchers will compare brain activity changes in 100 participants, including healthy cannabis users. The goa…

This study investigates whether abnormal insulin action in the brain contributes to cognitive and metabolic problems in schizophrenia. Twenty participants (some with schizophrenia, some healthy) will receive either intranasal insulin or a placebo before a PET scan that measures b…

This study is collecting blood samples and questionnaires from 1,100 people with bipolar disorder or schizophrenia. Researchers are looking for links between genetics, inflammation, and a dormant virus called HERV-W. The goal is to find new biomarkers and pave the way for future …

This study looks at how feeling lonely and being socially isolated affect the brain and daily life in people with serious mental illnesses like psychosis or schizophrenia. Researchers will use surveys, daily diaries, and brain scans to understand these connections. The goal is to…

This study uses a special PET scan tracer called [11-C]OMAR to measure cannabinoid receptors in the brain. Researchers will compare healthy volunteers to people with schizophrenia, cannabis dependence, PTSD, opioid use disorder, and other conditions. The goal is to understand how…

This study uses powerful 7T MRI scanners and visual perception tests to find biological markers for severe mental disorders like major depression, schizophrenia, and bipolar disorder. Researchers will compare brain chemistry and vision in 320 patients and healthy volunteers. The …

This study looks at how being in a hot room affects the body, thinking, and mood of people with schizophrenia. Ten adults with and without schizophrenia will sit in a warm or very hot room for six hours, doing light activity. The goal is to learn how heat impacts them so we can c…

This study creates a registry of brain scans, thinking tests, and blood samples from 1,000 people with schizophrenia, schizoaffective disorder, or no mental illness. Researchers use MRI to compare brain activity and connections between groups while performing memory tasks. The go…

This study tests whether a fast form of brain stimulation (accelerated iTBS) can improve thinking and memory in 30 adults with schizophrenia or schizoaffective disorder who are already taking the medication clozapine. Participants will receive both real stimulation and a sham (fa…

This study explores whether a gentle electrical current applied to the scalp (tDCS) can improve attention, learning, and memory in people with schizophrenia. Researchers will compare stimulation during a task versus rest, and front versus back of the head. They will also measure …

This study looks at language difficulties in people with psychosis, including those at risk, experiencing a first episode, or diagnosed with schizophrenia. Researchers will give a full language test to 90 patients and compare results with a healthy control group. The goal is to b…

This study investigates how people with schizophrenia experience time and sensory information differently. Researchers will use a visual illusion task to see if small timing disruptions affect perception. The goal is to better understand the link between time processing and psych…

This study looks at how people with schizophrenia sense time through touch. Researchers measure finger movements and brain signals to see if problems with timing can help predict who might develop psychosis. The goal is to find early markers for better care.

This study explores whether a non-invasive magnetic brain stimulation technique (TMS) can temporarily improve how quickly people with psychotic disorders (like schizophrenia or bipolar) solve problems. About 95 participants will do thinking tasks and get brain scans before and af…

This study looks at how attention and thinking strategies influence decision-making and brain activity in people with schizophrenia or schizoaffective disorder compared to healthy volunteers. Participants will use a positive thinking strategy during a gambling task while having t…

This study uses virtual reality games and EEG brain scans to understand how people with schizophrenia or bipolar disorder experience the passage of time. Researchers will compare 120 participants (patients and healthy volunteers) as they perform tasks in virtual environments. The…

This study looks at how brain structure and gene activity in the blood are linked in people with early schizophrenia. About 1,899 participants, including healthy volunteers, will have brain scans and blood tests at the start and after one year of regular medication. The goal is t…

This study tests whether a gentle electrical current applied to the scalp (tDCS) can improve how people with schizophrenia recognize emotions in faces. Researchers will use brain scans to see if the stimulation changes activity in motion-processing areas. The goal is to understan…

This study looks at how people with schizophrenia experience nicotine withdrawal when they stop vaping or smoking for 24 hours. Researchers will compare withdrawal symptoms, mood, and thinking skills between daily vapers and daily smokers. The goal is to understand nicotine depen…

This study looks at 320 people with early psychosis to see if brain scans, eye-tracking, and electrical brain waves can predict how well they respond to treatment. Participants will have four visits over a year, including interviews, memory tests, and optional DNA samples. The go…

This study uses transcranial magnetic stimulation (TMS) to map brain circuits in 180 adults with depression, OCD, anxiety, or schizophrenia. Participants receive accelerated TMS over two days while completing behavioral tests and questionnaires. The goal is to understand which br…

This study looks at whether social isolation contributes to the early health problems seen in people with schizophrenia, who often die 10–20 years earlier than others. Researchers will follow 650 participants (500 with schizophrenia and 150 siblings) aged 40–70, tracking medical …

This study tests whether a type of brain stimulation called repetitive TMS can increase natural brain inhibition in 34 people with schizophrenia. The goal is to see if this change relates to better thinking and memory. Participants will receive five days of treatment and undergo …

This study uses high-resolution 7-Tesla MRI to examine how a part of the brain called the mediodorsal thalamus supports flexible thinking and decision-making. One hundred healthy adults will perform computer tasks while their brain activity is scanned. The goal is to understand w…

This study looks at whether brain activity synchronizes differently in people with schizophrenia during social interactions. Researchers will compare 100 participants—some with schizophrenia and some without—as they chat and do tasks together while wearing EEG caps. The goal is t…

This study uses a special brain scan (PET) to measure the density of connections between brain cells in people with psychotic disorders (like schizophrenia) or cannabis use disorder, compared to healthy volunteers. The goal is to understand how brain connection changes relate to …

This study is following 200 children and teens (ages 7-20) who have experienced psychosis to see if they fall into distinct subgroups. Researchers will use interviews, brain scans, and genetic tests to classify participants. The goal is to see if these subgroups predict how well …

This study uses a noninvasive technique called transcranial magnetic stimulation (TMS) to understand how hallucinations work in people with schizophrenia or schizoaffective disorder. Researchers will stimulate a specific brain circuit and measure changes in brain connectivity and…

This study is looking at 200 people with treatment-resistant schizophrenia who are starting clozapine. Researchers will measure immune markers in blood and spinal fluid, brain scans, and other tests before and after 12 weeks of treatment. The goal is to find biological signs that…

This study looks at 55 women who have a chronic (long-term) infection with the Toxoplasma parasite and also have a mental health condition like schizophrenia, depression, or bipolar disorder. Researchers want to see if tiny molecules called microRNAs in the blood can help tell th…

This study is looking at how people with conditions like schizophrenia, bipolar disorder, depression, and neurological diseases (such as Alzheimer's or stroke) perform on computer-based thinking tests. The goal is to create a detailed map of cognitive strengths and weaknesses acr…

This study is testing whether MRI brain scans can help predict which patients having their first psychotic episode will not respond to standard treatment. Researchers will scan 80 people aged 18-35 with schizophrenia or related disorders who have never taken antipsychotic medicat…

This study tests whether cognitive remediation—brain exercises with coaching—can improve thinking skills and reduce aggression in 30 forensic inpatients with conditions like psychosis, ADHD, or substance use. Participants will do exercises and be compared to an active control gro…

This pilot study uses MRI scans to investigate whether a small brain area called the inferior colliculi plays a role in auditory hallucinations in people with schizophrenia. Researchers will compare brain activity in 40 participants—20 with hallucinations and 20 without—while the…

This study tests a program called PRESTO that aims to identify and treat first-episode psychosis sooner. The program educates the public, trains frontline workers like doctors and teachers, and provides a mobile team to connect patients to care. Researchers will measure whether t…

This study looks at tiny particles called exosomes in the blood of people experiencing their first episode of schizophrenia. Researchers want to see if the genetic material inside these particles is linked to problems with thinking and memory. By studying 300 participants, they h…

This study looks at whether a gentle brain stimulation technique called tDCS can change the density of synapses (connections between brain cells) in people with schizophrenia. Researchers will use special PET scans to measure these changes in 20 participants. The goal is to under…

This study is testing whether a non-invasive brain stimulation technique called tDCS can improve executive functions—like working memory, attention, and decision-making—in people with conditions such as traumatic brain injury, depression, bipolar disorder, schizophrenia, ADHD, bo…

This study compares brain energy use, lactate, and glutamate levels in 75 people with schizophrenia and healthy volunteers using advanced MRI and PET scans. Researchers aim to see if brain glucose use is lower and lactate higher in schizophrenia, and if glutamate varies more. No …